Humanigen, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a HGENQ research report →
Companywww.humanigen.com
Humanigen, Inc. , a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response. The company is developing lenzilumab, an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF), to treat cytokine storm associated with COVID-19 for which it has completed a Phase 3 study and is the focus of a Phase 2/3 study sponsored by the NIH.
- CEO
- Cameron Durrant MBA
- IPO
- 2013
- Employees
- 6
- HQ
- Short Hills, NJ, US
Price Chart
Valuation
- Market Cap
- $23.82K
- P/E
- -0.00
- P/S
- 0.00
- P/B
- -0.00
- EV/EBITDA
- 0.15
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 100.00%
- Op Margin
- -2716.95%
- Net Margin
- -2793.87%
- ROE
- 199.39%
- ROIC
- 150.73%
Performance & Tape
- 52W High
- $0.21
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- -1.34
- Avg Volume
- 35.33K
Get TickerSpark's AI analysis on HGENQ
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our HGENQ Coverage
We haven't published any research on HGENQ yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate HGENQ Report →